帕利哌酮缓释片治疗精神分裂症20例

Study on Efficacy of Paliperidone Extended-Release Tablets in Treating Schizophrenia

目的探讨帕利哌酮缓释片治疗精神分裂症的疗效。方法将40例精神分裂症患者随机均分为两组,研究组服用帕利哌酮缓释片治疗,剂量6～12 mg/d,对照组予氯丙嗪片治疗,剂量400～600 mg/d,疗程均为8周。于治疗前和治疗后第2周末、第4周末、第8周末用阳性与阴性症状量表(PANSS)评定疗效,用个人和社会功能量表(PSP)评定社会功能。结果所有患者PANSS评分和PSP评分治疗前后均有显著性差异(P<0.01),研究组PANSS评分于治疗第4周末显著低于对照组(P<0.05),PSP评分于第2周末极显著高于对照组(P<0.01)。结论帕利哌酮缓释片治疗精神分裂症能够较氯丙嗪片更显著地改善症状、提高患者社会功能。

Objective To explore the efficacies of Paliperidone Extended-Release Tablets in the treatment of schizophrenia.Methods Forty patients with schizophrenia were randomly and evenly assigned to the study group receiving Paliperidone Extended-Release Tablets treatment（n=20,6-12 mg/d） and the control group receiving chlorpromazine treatment（n=20,400-600 mg/d） for 8 weeks.The Positive and Negative Syndrome Scale（PANSS） and Personal and Social Performance scale（PSP） were used to evaluate the efficacies and patients′social function at the baseline and at the end of 2,4,8 weeks respectively.Results The scores of PANSS and PSP before and after medication in all the cases showed significant differences（P 0.01）.The PANSS score of the study group at the end of 4 weeks was significantly lower than that of the control group（P 0.05）.The PSP score of the study group at the end of 2 weeks was extremely significantly higher than that of the control group（P 0.01）.Conclusion Compared with chlorpromazine,Paliperidone Extended-Release Tablets can significantly relieve the symptoms of schizophrenia and improve the social function of the patients.